What is ldelalisib?

Idelalisib, also known by its commercial nameZydelig, is a targeted drug used to treat certain types of leukemia and lymphoma. Its pharmacological action is based on the inhibition of phospholipase Cδ (PI3Kδ), a protein that plays a key role in the immune system and blood cells. By targeting inhibition of PI3Kδ, idelaliside can interfere with the abnormal proliferation and survival of leukemia and lymphoma cells, thereby slowing the progression of the disease.

Idelalistat is approved to treat two main types of the disease, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Both diseases are related to B cells, and the mechanism of idelalix can specifically affect these abnormally proliferating cells and help alleviate disease symptoms.

The drug is usually given as an oral tablet, and dosage and administration vary depending on the patient's disease state, severity, and individual differences. Therefore, patients must strictly follow the doctor's recommendations to ensure the best therapeutic effect. In addition, the use of idelalix may be associated with a series of adverse reactions, including diarrhea, fatigue, fever, infection, dyspnea, etc. The severity of these adverse reactions varies among individuals and requires close monitoring and medical management.

Before using idelalix, patients should inform their physician of their comprehensive medical history and drug allergies to avoid potential drug interactions and adverse reactions. In addition, regular blood tests and physical examinations are essential to monitor efficacy and adverse effects. If patients experience any unusual symptoms or discomfort during treatment, they should communicate with their doctor in time.

Idelalis is not currently on the market in China, so it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase it through overseas channels. There are only original drugs of iderallis available abroad, mainly from the United States, and the price is as high as about 38,000 yuan.